Member Info for 1pencil

Well we are here, with the advent of SpaceX, OpenAi now filing papers for public offerings.

The backdrop to all of this is massively scaled back plans for the whole platform thing, Ai is never going to be a flop its a really useful tool but the extent of which is was pushed as a panacea to all humanities ills was just crazy..

Hoping this marks the peak of that insanity and the world can move on to a more stable environment, comparing SMS's latest interview below with one 12 months ago there is a notice change in Ai references, maybe that's just a coincidence though..

Lets see how these trillion dollar valuations stack up when fund managers have to cough up hard cash.

July will certainly be a watershed event, very much looking forward to the tide going out although I suspect there will be the odd comment that 'shorts' have now moved under the new threshold,..or sold out the day before..

Have a look at pairs trading, most likely option I can suggest having worked on these way back before they became popular..

Step back and think logically for a moment, apply the same rules to the stock market as you would in other areas of life.

Where else would you say 2% control the other 98% ..?

MP gets a mention, also highlights new protein trends

https://www.dairyreporter.com/Article/2026/05/19/whey-prices-protein-demand-and-the-shift-to-nutrition-platforms/

Only one sentence mentioning Ai, how times change..

Its standard practice for any market dealing to have shorts in order to buy stock, we only see one side of the trade so pretty irrelevant imo.

Take a look at my earlier post on this referencing deutsche bank recently.

Bit more mundane me thinks, see iShares..

Should read:

Often in my experience what constitutes a RNS release is fairly complex and not straightforward, at a guess I would say its 50/50.

It could be THG have already received the refund hence the drop in VAT being charged on certain product lines.

Often in my experience what constitutes a release is fairly complex and not straightforward, at a guess I would say its 50/50.

Okay, link blocked for some reason , here is the main page:

https://di.hkex.com.hk/di/NSSrchMethod.aspx?src=MAIN&lang=EN&in=1&

Select the top options 1. Search by listed corporation (stock code or name of the listed corporation)

it feels like market makers being overly aggressive, i think deutsche bank have a lot of control being the adr sponsor and market maker in hk.

its worth noting also that hk require disclosures of short positions by market makers, this would explain the usually large disclosure on the sfc web site which is pretty close to some of the deutsche bank filings here (link truncated):

********************bdz3arf7

box 18 shows both long and short positions, this is from last year but helps explain whats going on.

City sounds alarm on £40bn foreign M&A offensive targeting ‘cheap’ UK firms

https://www.cityam.com/stock-market-city-grandees-sound-alarm-on-foreign-offensive/

City sounds alarm on £40bn foreign M&A offensive targeting ‘cheap’ UK firms

https://www.cityam.com/stock-market-city-grandees-sound-alarm-on-foreign-offensive/

More commentary on Bristol Myers Squibb deal..

“It’s a huge signal,” said Michael Baran, head of private investments at healthcare-focused hedge fund Affinity Asset Advisors and a former partner at Pfizer Ventures. He said U.S. drugmakers have partnered with Chinese companies to develop drugs before, including Amgen’s 2019 collaboration with BeOne.

But Bristol’s deal is significant because it is more reciprocal, he said. It raises the prospect that more U.S. drugmakers could increasingly carry out early drug development in China as they try to bring treatments to market more quickly, and that Chinese companies could start to become global powerhouses.

https://www.cnbc.com/2026/05/15/bristol-myers-squibb-turns-to-chinas-hengrui-to-replenish-pipeline.html

Https://www.xe.com/currencycharts/?from=USD&to=GBP&view=1M

Here's how Hong Kong (HKEX) exchange report holdings, this one is for Deutsche Bank

18. Total shares immediately before the relevant event:

Total number of shares Percentage figure (%)

Long position 44,675,970 5.12

Short position 44,675,970 5.12

19. Total shares immediately after the relevant event:

Total number of shares Percentage figure (%)

Long position 41,425,860 4.75

Short position 41,425,860 4.75

Spire Heath-care bid received today

https://www.lse.co.uk/news/SPI/londons-spire-healthcare-gets-135-billion-buyout-proposal-from-toscafund-hsw8qcvs49op6b2.html

Plus Tate, just goes to show how under valued many of these listed companies are..

That should help hit forecasts for 2026, is it sufficient to trigger further milestone payments, think the last one was $20m for crossing $200m of sales back in 2024.

Plus the deal sector is on the boil - helps with US China relations especially with Trump headed there this wk..

Jiangsu Hengrui Pharmaceutical, China’s largest drug company by market capitalisation, has signed a global collaboration and licensing agreement with US pharmaceutical giant Bristol Myers Squibb (BMS) worth up to US$15.2 billion.

Hengrui’s Hong Kong-traded shares climbed 5.3 per cent to HK$69.55 on Tuesday, while its Shenzhen stock rose 4.84 per cent to 56.11 yuan.

The deal adds credibility to China’s growing reputation for innovative drug development. Industry players, however, said the country still had some way to go before it gained a “genuine voice” in the global pharmaceutical industry.

https://www.scmp.com/business/china-business/article/3353263/chinas-hengrui-seals-us152-billion-deal-us-pharmaceutical-giant-bms?

The risk/reward seems favourable, increased weighting here over last few days sub 200p.

Basically, there is optionality with so many irons in the fire, I think its fairly likely we will hear of an ATTC partner shortly which may help if there is an up front payment, the next 12 - 18 months also has a lot of potential candidates coming forward with possible validation, company has minimal debt ad $1.4b cash on hand with a market cap of just £1.62b ?